Diaz-Cartelle Juan 4

What Happened
Juan Diaz-Cartelle, Chief Medical Officer of Microbot Medical (MBOT), received a derivative equity award for 105,000 shares reported on a Form 4 covering a Feb 18, 2026 grant. The filing lists an acquisition price of $0.00, indicating no cash was paid by the insider for the award; the award is governed by the issuer’s 2020 Omnibus Performance Award Plan.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (timely).
• Security: derivative equity award (options) for 105,000 shares.
• Reported acquisition price: $0.00 (no cash paid).
• Shares owned after the transaction: not disclosed in the filing.
• Important footnote: Vesting per the Plan — 25% vests and becomes exercisable on August 18, 2026; the remaining 75% vests equally on a quarterly basis over the next 30 months, subject to acceleration or forfeiture per plan terms.
• Filing status: appears timely (filed within two business days of the transaction).

Context
This was an equity award (options) granted as compensation, not a purchase or sale of existing shares. Such awards vest over time and are typically intended for retention/incentive purposes; they do not represent immediate cash value unless exercised and/or in the money. The filing does not disclose exercise strike price or post-transaction holdings, so immediate economic value and dilution impact cannot be determined from this Form 4 alone.